was performed. Results: There was no correlation between pre-transplant DSA and the development of BOS (BOS stage 2/3 vs 0/1) p 0.22, or stages of BOS p 0.48. Similarly, there was no correlation between any of the pretransplant clinical factors and the development of BOS in patients surviving greater than one year in the presence of preformed DSA or non-DSA. Graft ischaemic time, HLA-mismatches, underlying disease and number of infections requiring hospital admission after transplantation did not have significant impact on the presence of BOS. Conclusions: Whilst pre-transplant donor specific HLA antibodies are known to have a deleterious effect on graft outcome in the early posttransplant period, it would appear from this preliminary data that in patients who survive despite having DSA there is no effect on subsequent development of BOS.